The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Illumina and University of Oxford to Sequence 500 Whole Human Genomes for Rare Disease Research

<p class='bwalignc'> <i>Opportunity to Bring Personalized Medicine to the Forefront of Healthcare</i> </p>

Wednesday, August 03, 2011

Illumina and University of Oxford to Sequence 500 Whole Human Genomes for Rare Disease Research03:01 EDT Wednesday, August 03, 2011 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes. Clinicians and geneticists at Oxford will analyze the data generated by Illumina's technology to evaluate patients' genomes in an effort to identify mutations that may be validated, used to diagnose their diseases, and inform potential treatment options. As a prelude to this effort, the team solicited cases from the Oxford clinical community to gain insight into the range of patients and diseases that might benefit most directly from whole-genome sequencing. The project will focus primarily on cancer, immunological disorders, and rare Mendelian diseases, all involving mutations that would be difficult or impossible to discover by standard genetic tests. “This collaboration represents a remarkable and very important step toward using whole-genome sequencing for translational medicine – where a patient's individual genetic information can be used to make key healthcare decisions,” said David Bentley, Vice President and Chief Scientist at Illumina. “We are excited to be working with Oxford on this effort. This collaboration also will help Illumina advance its technology to better meet the specific needs of clinical environments.” The team believes that the collaboration will demonstrate the enormous value that next-generation sequencing holds for clinical research, as it empowers clinicians and geneticists to evaluate the genetic basis of diseases with a previously unmatched level of precision. The collaboration has already had its first exciting breakthrough―information obtained by sequencing the genomes of a family revealed a de novo genetic mutation hypothesized to be responsible for a life-threatening cranial developmental defect in a four-year–old girl. Oxford clinicians have been able to use the whole-genome sequence information to identify mutations that, when validated, enable them to properly diagnose the disorder, evaluate potential healthcare options, and provide her family with genetic counseling. “This case demonstrates the great potential of next-generation sequencing technology to elucidate the underlying genetic causes of disorders that are difficult to diagnose,” said Professor Peter Donnelly, Director of the Wellcome Trust Centre for Human Genetics at the University of Oxford. “Our collaboration with Illumina, studying over a hundred different diseases, will allow us to explore the value of whole-genome sequencing in clinical medicine in informing diagnosis and treatment decisions for patients. The initiative represents a crucial step as we move towards a new healthcare paradigm in which genetic information from next-generation sequencing is likely to become much more widely used in routine medical practice.” As part of the collaboration, Illumina will sequence 100 genomes at its Chesterford site in the U.K. The remaining 400 genomes will be sequenced using HiSeq 2000 systems at the Wellcome Trust Centre for Human Genetics in Oxford. Illumina is also working to bring whole-genome sequencing to patients worldwide through our Individual Sequencing Service (IGS), featuring the Company's CLIA certified / CAP accredited clinical services laboratory. Please visit for more details. About Illumina Illumina ( is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release contains forward-looking statements that involve risks and uncertainties, including statements we make regarding the ability of the collaboration to demonstrate the value that next-generation sequencing holds for clinical research. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. Illumina, Inc.Investors:Kevin Williams, MDInvestor Relations858-332-4989kwilliams@illumina.comorMedia:Laura TrotterPublic